Loading…
Nureca (NURECA)₹302.10−0.72%Medical Equipment & Supplies
In the Sep 2026 quarter (consolidated), Nureca reported sales of ₹58.62 Cr, up 55.0% from Sep 2025, and net profit of ₹4.04 Cr, up 11.6% year on year. For the year to Mar 2026, sales were ₹147 Cr and net profit ₹1.99 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.41 | 17.00 | 20.30 | 31.26 | 26.52 | 31.79 | 34.25 | 37.82 | 39.72 | 35.45 | 40.40 | 58.62 |
| Expenses | 26.59 | 21.35 | 22.57 | 33.49 | 30.42 | 30.48 | 34.66 | 34.38 | 36.34 | 41.08 | 36.82 | 53.17 |
| Operating Profit | −4.24 | −4.42 | −2.37 | −2.34 | −4.00 | 1.21 | −0.55 | 3.28 | 3.24 | −5.77 | 3.43 | 5.22 |
| OPM % | −19.0% | −26.1% | −11.6% | −7.5% | −15.1% | 3.8% | −1.6% | 8.7% | 8.2% | −16.3% | 8.5% | 9.0% |
| Other Income | 5.92 | −1.27 | 5.81 | 3.18 | 1.49 | 2.00 | 2.58 | 2.33 | 2.20 | 1.03 | 1.83 | 1.36 |
| Interest | 0.12 | 0.19 | 0.16 | 0.28 | 0.19 | 0.63 | 0.26 | 0.47 | 0.29 | 0.31 | 0.21 | 0.27 |
| Depreciation | 0.58 | 0.59 | 0.65 | 0.61 | 0.53 | 0.51 | 0.52 | 0.53 | 0.49 | 0.44 | 0.60 | 0.80 |
| Profit before tax | 0.96 | −6.49 | 2.63 | −0.08 | −3.26 | 2.06 | 1.24 | 4.60 | 4.67 | −5.53 | 4.44 | 5.52 |
| Tax % | 82.1% | −35.9% | 36.6% | 585.7% | −13.9% | −20.0% | 34.1% | 21.1% | 20.0% | 10.7% | 30.9% | 26.5% |
| Net Profit | 0.16 | −4.16 | 1.65 | −0.47 | −2.81 | 2.46 | 0.80 | 3.62 | 3.74 | −6.08 | 3.06 | 4.04 |
| EPS (Rs) | 0.18 | −4.17 | 1.67 | −0.49 | −2.81 | 2.48 | 0.82 | 3.64 | 3.92 | −6.41 | 3.23 | 4.26 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 62.11 | 99.19 | 214 | 256 | 111 | 92.16 | 110 | 147 | 174 |
| Expenses | 52.91 | 89.82 | 152 | 200 | 126 | 102 | 117 | 147 | 167 |
| Operating Profit | 8.99 | 9.99 | 62.01 | 55.96 | −15.01 | −9.99 | −8.01 | 0.00 | 6.12 |
| OPM % | 15.1% | 10.0% | 29.1% | 22.1% | −12.9% | −11.0% | −7.0% | 0.1% | 3.5% |
| Other Income | 0.00 | 0.00 | 3.01 | 8.02 | 7.01 | 11.03 | 12.03 | 8.02 | 6.42 |
| Interest | 0.00 | 1.01 | 2.01 | 1.01 | 0.00 | 0.00 | 1.01 | 1.01 | 1.08 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.33 |
| Profit before tax | 9.02 | 9.02 | 62.18 | 61.16 | −11.02 | −3.01 | 1.01 | 5.01 | 9.10 |
| Tax % | 30.0% | 26.0% | 26.0% | 26.0% | −23.1% | −30.0% | 37.0% | 58.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 4.01 | 0.00 | 0.00 | — |
| Net Profit | 6.01 | 5.99 | 45.98 | 44.97 | −7.99 | −2.01 | 0.99 | 1.99 | 4.76 |
| EPS (Rs) | 625.30 | 642.32 | 46.55 | 45.15 | −8.28 | −1.80 | 0.86 | 2.19 | 5.00 |
| Dividend payout % | 0.0% | 0.0% | 4.0% | 7.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.02 | 0.02 | 10.01 | 10.01 | 10.02 | 10.02 | 10.02 | 10.01 |
| Reserves | 8.02 | 15.04 | 153 | 193 | 186 | 183 | 184 | 171 |
| Borrowings | 0.00 | 9.97 | 3.99 | 3.99 | 2.99 | 2.99 | 4.99 | 1.99 |
| Other Liabilities | 15.01 | 9.04 | 18.91 | 11.94 | 7.96 | 10.04 | 10.94 | 12.94 |
| Total Liabilities | 24.04 | 34.06 | 186 | 219 | 207 | 205 | 210 | 196 |
| Fixed Assets | 1.01 | 1.01 | 4.01 | 10.02 | 9.02 | 7.02 | 9.02 | 14.03 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 33.13 | 59.20 | 94.31 | 1.01 | 1.01 |
| Other Assets | 23.03 | 33.05 | 182 | 175 | 139 | 104 | 200 | 182 |
| Inventories | 14.01 | 15.99 | 36.96 | 63.03 | 33.97 | 30.97 | 39.99 | 47.97 |
| Trade receivables | 9.03 | 13.04 | 4.01 | 3.01 | 4.01 | 2.01 | 3.01 | 8.02 |
| Cash & equivalents | 0.00 | 0.00 | 127 | 84.10 | 71.16 | 45.05 | 127 | 41.05 |
| Total Assets | 24.04 | 34.06 | 186 | 219 | 207 | 205 | 210 | 196 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −8.02 | 35.11 | 1.01 | 10.03 | −3.01 | −19.06 | 3.01 |
| Cash from investing activity | 0.00 | −110 | −2.99 | −15.98 | 17.97 | 7.99 | 13.99 |
| Cash from financing activity | 8.01 | 92.01 | −7.01 | −1.99 | −1.01 | 0.00 | −19.98 |
| Net cash flow | 0.00 | 17.05 | −9.03 | −8.03 | 14.05 | −11.05 | −2.01 |
| Capex | 0.00 | 1.01 | 6.01 | 0.00 | 1.01 | 4.01 | 7.02 |
| Free cash flow | −7.97 | 33.88 | −4.98 | 9.96 | −3.98 | −22.93 | −2.99 |
| CFO / OP % | −82.0% | 81.1% | 35.1% | −95.9% | 39.1% | 234.1% | 1,464.1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 51 | 46 | 5 | 3 | 13 | 5 | 10 | 18 |
| Inventory days | 122 | 92 | 134 | 173 | 166 | 185 | 213 | 186 |
| Days payable | 88 | 32 | 31 | 12 | 23 | 30 | 34 | 19 |
| Cash conversion cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working capital days | 44 | 84 | 60 | 108 | 155 | 175 | 162 | 144 |
| ROCE % | — | 57.0% | 67.0% | 33.0% | −6.0% | −4.0% | 1.0% | 3.0% |
For the Sep 2026 quarter, Nureca reported sales of ₹58.62 Cr, up 55.0% year on year and net profit of ₹4.04 Cr, up 11.6% year on year. The operating margin was 9.0%.
Nureca's sales for the year to Mar 2026 were ₹147 Cr; over the last twelve months they were ₹174 Cr.
Net profit for the year to Mar 2026 was ₹1.99 Cr, and ₹4.76 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.00.
Nureca reported borrowings of ₹1.99 Cr at Mar 2026, against cash and equivalents of ₹41.05 Cr.
Cash from operations was ₹3.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹2.99 Cr.